Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 10/20 | 0.40 |
| ▸ | JAK1 | P23458 | 10/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719348 | 0.88 | GPR119 (0.41) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL22719293 | 0.87 | MGLL (0.43) | TACR1JAK2JAK1GPR119 | |
| SCHEMBL3355141 | 0.84 | JAK2 (0.49) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL22719214 | 0.83 | GPR119 (0.42) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL22719164 | 0.83 | TACR1 (0.48) | TACR1JAK2JAK1GPR119 | |
| SCHEMBL22719333 | 0.81 | GPR119 (0.47) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL22719223 | 0.81 | TACR1 (0.45) | TACR1JAK2JAK1GPR119 | |
| SCHEMBL29453775 | 0.81 | TACR1 (0.45) | TACR1JAK2JAK1GPR119 | |
| SCHEMBL22719180 | 0.80 | JAK2 (0.47) | TACR1JAK2JAK1GPR119 | |
| SCHEMBL4635533 | 0.80 | JAK2 (0.47) | JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-3976186-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Sage Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243027-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYP46A1, CYP26A1, CYP21A2 | TACR1 1017/4885JAK2 2813/4885JAK1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.